Citations

Clear

171 citation(s) found for "Moss, M".

Abstract 12754: Infused CD34 Cell Dose, not Bone Marrow CD34+ Cell Content, Improves Clinical Outcomes and LVEF in Patients With Left Ventricular Dysfunction post STEMI: Results of the PreSERVE-AMI Trial
Kereiakes, Dean J. , Shavelle, David M. , Henry, Timothy D. , Toma, Catalin , Barsness, Gregory W. , Frohwein, Steve, Schatz, Richartd A, Cohen, Martin, Davidson, Charles J., Klapholz, Marc, Schaer, Gary L. , Moss, Thomas J. , Kanakaraj, AnnaMaria, Druker, Vitaly , Harper, Ken, Chung, Amy M. , Junge, Candice, Preti, Robert A., Smith, Robin L., Mazzo, David J., Pecora, Andrew L. , Quyyumi, Arshed A. , Abdel‐Latif, Ahmed , Schatz, R A, Dib, Nabil , Vásquez, Alejandro Arias , Kanakaraj, Anna Maria, Harper, Ken, Chung, Amy, Mazzo, David J., Losordo, Douglas W.

Mayo Clinic

Circulation | July 3, 2021 | Volume: 132 | Issue: suppl_3 | Pages: No page available

10.1161/circ.132.suppl_3.12754 Get It

Background: Prior studies suggest an association between naturally high circulating levels of CD34+ cells (CD34) and better outcomes following ischemic events. Pts in the treatment arm of the PreSERVE-AMI study were infused with all CD34 yielded from their bone marrow harvest, resulting in pts with naturally higher CD34 cell counts being infused with a higher cell dose. To determine whether selection bias may have influenced results, we performed an analysis of the relationship between BM CD34 content and outcomes in PreSERVE-AMI. Methods: PreSERVE-AMI is a Phase 2, randomized, double-blind, placebo-controlled trial of autologous, BM derived CD34 (CLBS10) in pts with LV dysfunction (LVEF ≤48% by MRI) ≥4 days post-STEMI. All pts underwent mini BM harvest and were randomized 1:1 to intracoronary infusion of CD34 (minimum dose 10M±20% cells) or placebo (cell diluent). Primary safety endpoints included AEs, SAEs and MACE (CV mortality, HF hospitalization, reinfarction, revascularization). Secondary endpoints included LVEF change from baseline. Regression analyses were performed to assess the influence of BM CD34 content on outcomes. Results: 161 patients were randomized and received intracoronary infusion (Jan 2013-Dec 2014). Mean age was 57±10 and 82% were men. Mean follow-up time was 18 mo, and safety data are accruing. BM CD34 content was not associated with differences in baseline characteristics with the exception of diabetes prevalence being higher in those with higher BM CD34 count (p=0.03). In controls, regression analyses showed no association of BM CD34 content with rates of MACE (p=0.2), SAEs (p=0.4), or change in LVEF (p=0.9). However, in CD34 treated pts, there was a dose-dependent improvement in LV function (p=0.045) and dose-dependent trends in MACE and SAE reduction compared to controls. As previously reported SPECT perfusion improved to a similar degree in control and treated pts. Conclusions: These data suggest that intracoronary infusion of CD34 cells, rather than BM CD34 cell content, is responsible for the benefit observed in the CD34 treatment group. The finding of a dose-response relationship is an important advance for defining the CD34 as an active agent for tissue repair. Future studies will further define CD34 dosimetry.
Correlation of Chronic Histologic Changes on Preimplantation Frozen Section Biopsy With Transplant Outcomes After Deceased Donor Kidney Transplantation
Ninan, Jacob, Smith, Maxwell L., Mathur, Amit K., Harbell, Jack W., Jadlowiec, Caroline C., Nair, Sumi Sukumaran, Moss, Adyr, Reddy, Kunam S., Heilman, Raymond L., Ninan, Jacob, Smith, Maxwell L., Mathur, Amit K., Harbell, Jack W., Jadlowiec, Caroline C., Nair, Sumi Sukumaran, Moss, Adyr, Reddy, Kunam S., Heilman, Raymond L.

Mayo Clinic

Archives of Pathology & Laboratory Medicine | June 4, 2021 | Volume: 146 | Issue: 2 | Pages: 205-212

10.5858/arpa.2020-0675-oa | PMID 34086859 Get It

Context.— It is unclear if preimplantation frozen section biopsy correlates with outcomes after deceased donor kidney transplantation. Objective.— To assess if chronic histologic changes on the preimplant frozen section correlates with graft loss and estimated glomerular filtration rate independently of kidney donor profile index (KDPI). Design.— Seven hundred three preimplantation biopsies were reviewed and a Banff sum score was calculated using glomerular sclerosis, interstitial fibrosis, vascular intimal thickening, and arteriolar hyalinosis. The posttransplant outcomes were compared for preimplantation biopsy Banff sum 0-1, 2-3, and 4-9. The cohort was also stratified by KDPI 85 or less versus more than 85. Results.— For the entire biopsy cohort, graft survival, estimated glomerular filtration rate at 1 year, and chronic changes on a 1-year posttransplant biopsy were superior in the group with preimplantation Banff sum 0-1. After stratifying by KDPI, the Banff sum no longer correlated with graft survival. In a univariate mode, using the Banff sum score as a continuous variable, a higher Banff sum score was significantly associated with graft failure (P = .03); however, after adjusting the KDPI, the Banff sum score no longer correlated with graft failure (P = .45). The 1-year estimated glomerular filtration rate and 1-year biopsy changes were superior in the group with Banff sum 0-1 only in the cohort with KDPI 85 or less. Conclusions.— In donor kidneys used for transplant, preimplantation biopsy chronic changes correlate with estimated glomerular filtration rate and biopsy findings at 1 year, but biopsies with mostly mild chronicity and Banff sum scores less than or equal to 5 did not impact graft survival beyond KDPI.
Optic chiasm involvement in AQP-4 antibody–positive NMO and MOG antibody–associated disorder
Tajfirouz, Deena , Padungkiatsagul, Tanyatuth , Beres, Shannon , Moss, Heather E. , Pittock, Sean J. , Kunchok, Amy , Bhatti, M. Tariq , Chen, John J. , Flanagan, E P , Shah, Shailee , Pittock, S J , Pittock, Sean J , Chen, John J , Moss, Heather E , Flanagan, Eoin P.

Mayo Clinic

Multiple Sclerosis Journal | May 12, 2021 | Volume: 28 | Issue: 1 | Pages: 149-153

10.1177/13524585211011450 | PMID 33975499 Get It

Background: Optic neuritis (ON) is often the presenting symptom in inflammatory central nervous system demyelinating disorders. Objective: To compare the frequency and pattern of optic chiasm involvement in patients with aquaporin-4-immunoglobulin G (AQP4-IgG)-associated ON to patients with myelin oligodendrocyte glycoprotein-immunoglobulin G (MOG-IgG)-associated ON. Methods: Retrospective review of all patients evaluated at Mayo Clinic, Stanford University and Ramathibodi Hospital who were found to have: (1) ON, (2) either MOG-IgG or AQP4-IgG by cell-based assay, and (3) magnetic resonance imaging (MRI) at the time of ON. MRI was reviewed for contrast enhancement of the optic chiasm and the pattern of involvement. Results: One hundred and fifty-four patients (74 AQP4-IgG and 80 MOG-IgG) were included. Among patients with AQP4-IgG-ON, 20% had chiasmal involvement, compared with 16% of patients with MOG-IgG-ON ( p = 0.66). In patients with chiasmal involvement, longitudinally extensive optic nerve enhancement (from orbit extending to chiasm) was identified in 54% of MOG-IgG-ON patients, compared with 7% of AQP4-IgG-ON patients ( p = 0.01). Conclusion: Chiasmal involvement of MOG-IgG-ON and AQP4-IgG-ON occur at more similar frequencies than previously reported. Furthermore, MOG-IgG-ON chiasmal involvement is more likely to be part of a longitudinally extensive optic nerve lesion.
The Utility of Serial Right Heart Catheterizations in Patients with Model for End Stage Liver Disease Exceptions for Portopulmonary Hypertension
Kay, D., Krowka, Michael J. , Cartin‐Ceba, Rodrigo , Burger, C.D., Moss, James , Heimbach, Julie K. , Cajigas, Héctor , DuBrock, Hilary M.

Mayo Clinic

TP82. TP082 LET IT BE - CLINICAL ADVANCES IN PULMONARY VASCULAR DISEASE: PAH AND BEYOND | May 4, 2021 | Volume: No volume available | Issue: No issue available | Pages: A3589-A3589

10.1164/ajrccm-conference.2021.203.1_meetingabstracts.a3589 Get It

British Society of Gastroenterology guidelines on the management of irritable bowel syndrome
Vasant, Dipesh H. , Paine, Peter , Black, Christopher J. , Houghton, Lesley A. , Everitt, Hazel , Corsetti, Maura , Aziz, Imran , Farmer, Adam D. , Eugenicos, Maria , Moss‐Morris, Rona , Yiannakou, Yan , Ford, Alexander C. , Aziz, Imran , Ford, Alexander C , Houghton, L A , Corsetti, M , Black, Christopher J , Vasant, Dipesh H , Farmer, Adam D , Agrawal, Anurag

Mayo Clinic

Gut | April 26, 2021 | Volume: 70 | Issue: 7 | Pages: 1214-1240

10.1136/gutjnl-2021-324598 | PMID 33903147 Get It

Irritable bowel syndrome (IBS) remains one of the most common gastrointestinal disorders seen by clinicians in both primary and secondary care. Since publication of the last British Society of Gastroenterology (BSG) guideline in 2007, substantial advances have been made in understanding its complex pathophysiology, resulting in its re-classification as a disorder of gut-brain interaction, rather than a functional gastrointestinal disorder. Moreover, there has been a considerable amount of new evidence published concerning the diagnosis, investigation and management of IBS. The primary aim of this guideline, commissioned by the BSG, is to review and summarise the current evidence to inform and guide clinical practice, by providing a practical framework for evidence-based management of patients. One of the strengths of this guideline is that the recommendations for treatment are based on evidence derived from a comprehensive search of the medical literature, which was used to inform an update of a series of trial-based and network meta-analyses assessing the efficacy of dietary, pharmacological and psychological therapies in treating IBS. Specific recommendations have been made according to the Grading of Recommendations Assessment, Development and Evaluation system, summarising both the strength of the recommendations and the overall quality of evidence. Finally, this guideline identifies novel treatments that are in development, as well as highlighting areas of unmet need for future research.
Patterns of Functional Change Five to Ten Years after Moderate-Severe Traumatic Brain Injury
Malec, James F. , Whiteneck, Gale G. , Hart, Tessa , Novack, Thomas A. , Bogner, Jennifer , Dahdah, Marie N. , Eagye, C.B. , Sevigny, Mitch , Ketchum, Jessica M. , Hammond, Flora M. , Corrigan, John D. , Dams-O’Connor, Kristen

Mayo Clinic

Journal of Neurotrauma | March 27, 2021 | Volume: 38 | Issue: 11 | Pages: 1526-1534

10.1089/neu.2020.7499 | PMID 33779295 Get It

This study aims to characterize the patterns of functional change experienced between 5 and 10 years after moderate-severe traumatic brain injury (TBI). The study included TBI Model Systems national database participants ( N = 372) at six sites who experienced TBI, received inpatient rehabilitation, and were followed at 5 and 10 years post-TBI. Outcome measures included self- or proxy-reported Functional Independence Measure (FIM TM ) structured interview at 5 and 10 years post-TBI and domain change indices (DCIs) at 10 years to assess subjective change over the previous 5 years. When all seven FIM and subjective DCI subscales were considered together, 69% reported improvement in at least one subscale and 41% reported decline in at least one subscale; 51% reported more domains improved than declined, and 20% reported more domains declined than improved. Age at injury, post-traumatic amnesia duration, FIM, and depression and anxiety at year 5 were associated with FIM change and DCI measures. Although most persons with moderate-severe TBI do not experience widespread change from year 5 to 10 on individual FIM subscales or perceived domain-specific subscales, the vast majority do report change in one or more domains, with more improvement than decline and more change in subjective DCI than in FIM. Clinicians and researchers should be alert to the possibility of both positive and deleterious changes many years after TBI.
Transplant outcomes using kidneys from high KDPI acute kidney injury donors
Hanna, W. A., Ninan, Jacob, Ryan, Margaret , Das, Devika , Khamash, Hasan , Mathur, Amit K. , Singer, Andrew L., Moss, Adyr A. , Reddy, Kunam S. , Heilman, Raymond L. , Jadlowiec, Caroline , Hanna, Wael A, Ryan, Margaret S, Das, Devika M, Mathur, Amit , Singer, Andrew, Das, Devika , Jadlowiec, Caroline C. , Hanna, Wael A., Smith, Maxwell L.

Mayo Clinic

Clinical Transplantation | March 10, 2021 | Volume: 35 | Issue: 5 | Pages: No page available

10.1111/ctr.14279 | PMID 33690907 Get It

AbstractKidney transplant (KT) outcomes from high kidney donor profile index (KDPI ≥85%) donors with acute kidney injury (AKI) remain underreported. KT from 172 high KDPI Acute Kidney Injury Network (AKIN) stage 0‐1 donors and 76 high KDPI AKIN stage 2‐3 donors from a single center were retrospectively assessed. The AKIN 2‐3 cohort had more delayed graft function (71% vs. 37%, p < .001). At one year, there were no differences in the estimated glomerular filtration rate (44 ± 17 vs. 46 ± 18, p = .42) or fibrosis on protocol biopsy (ci, p = .85). Donor terminal creatinine (p = .59) and length of delayed graft function (p = .39) did not impact one‐year eGFR. There were more primary nonfunction (PNF) events in the high KDPI AKIN 2‐3 group (5.3% vs. 0.6%, p = .02). With a median follow‐up of 3.8 years, one‐year death‐censored graft failure was 3.5% for AKIN 0‐1 and 14.5% for AKIN 2‐3 (HR 2.40, 95% CI 1.24‐4.63, p = .01). Although AKIN stage 2‐3 high KDPI kidneys had comparable one‐year eGFR to AKIN stage 0‐1 high KDPI kidneys, there were more PNF occurrences and one‐year death‐censored graft survival was reduced. Given these findings, additional precautions should be undertaken when assessing and utilizing kidneys from severe AKI high KDPI donors.
Prevalence of Glucose-6-Phosphate Dehydrogenase Deficiency and Gametocytemia in a Pre-Elimination, Low Malaria Transmission Setting in Southern Zambia
Kobayashi, Tamaki , Kurani, Shaheen , Hamapumbu, Harry, Stevenson, Jennifer C. , Thuma, Philip E. , Moss, William J. , _, _, _, _

Mayo Clinic

The American Journal of Tropical Medicine and Hygiene | January 5, 2021 | Volume: 104 | Issue: 3 | Pages: 1000-1002

10.4269/ajtmh.20-1187 | PMID 33399042 Get It

ABSTRACTThe WHO recommends single low-dose (SLD) primaquine as a gametocytocide to reduce Plasmodium falciparum transmission in areas of low transmission. Despite this recommendation, uptake of SLD primaquine has been low because of concerns of glucose-6-phosphate dehydrogenase (G6PD) deficiency. Individuals with G6PD deficiency can experience hemolysis when exposed to primaquine. In Southern Province, Zambia, malaria transmission has declined significantly over the past decade. Single low-dose primaquine may be an effective tool, but there is limited information on G6PD deficiency. We screened 137 residents in Macha, Southern Province, Zambia, and the prevalence of G6PD (A−) was 15%. We also revisited data collected from 2008 to 2013 in the same area and found the highest gametocyte burden among those aged 5–15 years. The findings from this study suggest that SLD primaquine targeted to school-aged children may be an effective tool to help achieve malaria elimination in southern Zambia.
436: A Rare Cause of Hypercapnic Respiratory Failure: Hypothyroid Myopathy
Lugo‐Fagundo, Nahyr , Shah, Kejal, Nelson, Lauren Hassan, Turcano, Pierpaolo , Moss, John, Helgeson, Scott A. , Nelson, Lauren Juliette Hassan, Moss, John E. , Chaudhary, Sanjay , Guru, Pramod

Mayo Clinic

Critical Care Medicine | December 18, 2020 | Volume: 49 | Issue: 1 | Pages: 208-208

10.1097/01.ccm.0000727632.06388.79 Get It

OUTCOMES OF NON-LIVER SOLID ORGAN TRANSPLANTATION USING HEPATITIS C POSITIVE DONORS TO HEPATITIS C NEGATIVE RECIPIENTS: A MULTICENTER EXPERIENCE
Ryland, Kristen, Aqel, Bashar , Erasmus, D , Patel, Parag C. , Steidley, D. Eric , Huskey, Janna L. , Moss, Adyr A. , Aqel, Bashar A. , Mallea, Jorge M. , Mao, Shennen A. , Pham, Si M. , Pungpapong, Surakit

Mayo Clinic

Transplantation | August 28, 2020 | Volume: 104 | Issue: S3 | Pages: S108-S109

10.1097/01.tp.0000698820.36121.10 Get It